Simplifying psychotropic medication regimen into a single night dosage and reducing the dose for patients with chronic schizophrenia
- PMID: 15991004
- DOI: 10.1007/s00213-005-0018-3
Simplifying psychotropic medication regimen into a single night dosage and reducing the dose for patients with chronic schizophrenia
Abstract
Rationale: Taking psychotropic medications is frequently problematic from both consumers' and caregivers' perspective. Occasionally missed doses may lead to pervasive non-adherence with relapse a likely outcome.
Objective: To evaluate the simple medication regimen, all psychotropics were given at night for patients with chronic schizophrenia, who had been taking them at least twice a day for more than 12 weeks before the entry.
Methods: Switching of agents took place in two ways: converting only antipsychotic medications followed by other psychotropics, and changing all psychotropics simultaneously. Any psychotropics of little clinical significance were then cautiously minimized. Final evaluation was made 12 weeks after the competed dose consolidation. Patients finally rated their subjective impression on this intervention.
Results: Twenty-five patients were recruited in each treatment arm (50 in total). After switching, 11 got better, 29 remained stable whereas seven got worse, according to the Global Improvement. Three were not assessable. Overall, there were no relevant changes in clinical ratings including adverse effects. However, the chlorpromazine equivalent dose of antipsychotics and the number of total psychotropics were significantly reduced from 957 to 722 mg/day (p<0.0001) and from 4.0 to 3.2 (p<0.0001), respectively. Dose deflation of psychotropics was feasible in 35 subjects (74.5%). Twenty-six (of 40 successful) patients indicated that they favored the night-time regimen mainly because it was less complicated. Sedation in the morning was identified as an important adverse event, which should be addressed by reducing the dose.
Conclusions: The procedure may be of value to counteract a recent trend of psychotropic polypharmacy in schizophrenia.
Similar articles
-
Revising polypharmacy to a single antipsychotic regimen for patients with chronic schizophrenia.Int J Neuropsychopharmacol. 2004 Jun;7(2):133-42. doi: 10.1017/S1461145703004012. Epub 2004 Jan 23. Int J Neuropsychopharmacol. 2004. PMID: 14741059 Clinical Trial.
-
A clinical case series of switching from antipsychotic polypharmacy to monotherapy with a second-generation agent on patients with chronic schizophrenia.Prog Neuropsychopharmacol Biol Psychiatry. 2004 Mar;28(2):361-9. doi: 10.1016/j.pnpbp.2003.11.006. Prog Neuropsychopharmacol Biol Psychiatry. 2004. PMID: 14751434 Clinical Trial.
-
Concomitant medications may not improve outcome of antipsychotic monotherapy for stabilized patients with nonacute schizophrenia.J Clin Psychiatry. 2006 Aug;67(8):1261-5. doi: 10.4088/jcp.v67n0813. J Clin Psychiatry. 2006. PMID: 16965205 Clinical Trial.
-
Management of treatment resistant schizophrenia unresponsive to clozapine.Br J Psychiatry Suppl. 1996 Dec;(31):31-40. Br J Psychiatry Suppl. 1996. PMID: 8968653 Review. No abstract available.
-
[Is it valid to concurrently use multiple antipsychotics for patients with schizophrenia?].Nihon Shinkei Seishin Yakurigaku Zasshi. 2005 Aug;25(4):159-68. Nihon Shinkei Seishin Yakurigaku Zasshi. 2005. PMID: 16190364 Review. Japanese.
Cited by
-
Defining and assessing adherence to oral antipsychotics: a review of the literature.Schizophr Bull. 2006 Oct;32(4):724-42. doi: 10.1093/schbul/sbj075. Epub 2006 May 17. Schizophr Bull. 2006. PMID: 16707778 Free PMC article. Review.
-
Impact of Medication Regimen Simplification on Medication Adherence and Clinical Outcomes in Patients with Long-Term Medical Conditions.Patient Prefer Adherence. 2020 Nov 2;14:2135-2145. doi: 10.2147/PPA.S268499. eCollection 2020. Patient Prefer Adherence. 2020. PMID: 33173282 Free PMC article. Review.
-
How effective is it to sequentially switch among Olanzapine, Quetiapine and Risperidone?--A randomized, open-label study of algorithm-based antipsychotic treatment to patients with symptomatic schizophrenia in the real-world clinical setting.Psychopharmacology (Berl). 2007 Dec;195(2):285-95. doi: 10.1007/s00213-007-0872-2. Epub 2007 Aug 14. Psychopharmacology (Berl). 2007. PMID: 17701027 Clinical Trial.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical